DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Information source: Samsung Bioepis Co., Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rheumatoid Arthritis

Intervention: Humira (adalimumab) (Drug); SB5 (proposed biosimilar to adalimumab) (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Samsung Bioepis Co., Ltd.

Official(s) and/or principal investigator(s):
Asta Baranauskaite, M.D., Ph.D., Principal Investigator, Affiliation: Hospital of Lithuanian University of Health Sciences

Summary

This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira in subjects with moderate to severe RA despite MTX therapy.

Clinical Details

Official title: A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: American College of Rheumatology 20% response criteria (ACR20)

Secondary outcome:

ACR20

American College of Rheumatology 50% response criteria (ACR50)

Disease activity score based on a 28 joint count (DAS28)

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Are male or female aged 18-75 years at the time of signing the informed consent form.

- Have been diagnosed as having RA according to the revised 1987 American College of

Rheumatology (ACR) criteria for at least 6 months but not exceeding 15 years prior to Screening.

- Have moderate to severe active disease despite MTX therapy defined as:

1. More than or equal to six swollen joints and more than or equal to six tender joints (from the 66/68 joint count system) at Screening and Randomisation. 2. Either erythrocyte sedimentation rate (Westergren) ≥ 28 mm/h or serum C-reactive protein ≥ 1. 0 mg/dL at Screening.

- Must have been treated with MTX for a total of at least 6 months prior to

Randomisation and must have been on both: a stable route of administration (oral or parenteral) and stable dose of MTX (10-25 mg/week) for at least 4 weeks prior to Screening.

- Female subjects who are not pregnant or nursing at Screening and Randomisation and

who are not planning to become pregnant from Screening until 5 months after the last dose of IP. Exclusion Criteria:

- Have been treated previously with any biological agents including any tumour necrosis

factor inhibitor.

- Have a known hypersensitivity to human immunoglobulin proteins or other components of

Humira or SB5.

- Have a positive serological test for hepatitis B or hepatitis C or have a known

history of infection with human immunodeficiency virus.

- Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a

person with active TB, or are considered to have latent TB.

- Have had a serious infection or have been treated with intravenous antibiotics for an

infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.

- Have a history of chronic or recurrent infection.

- Have any of the following conditions:

1. History of congestive heart failure (New York Heart Association Class III/IV). 2. History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening. 3. History of demyelinating disorders. 4. History of any malignancy within the previous 5 years prior to Screening. 5. History of lymphoproliferative disease including lymphoma. 6. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.

- Have physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).

Locations and Contacts

Investigational Site, Kaunas, Lithuania

Investigational site, Katowice, Poland

Additional Information

Starting date: May 2014
Last updated: May 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017